SNBL At a Glance

We focus on the life sciences field, primarily engaging in three main businesses centered around contract research and development of pharmaceuticals for pharmaceutical companies.

1. CRO business that undertakes all processes of pharmaceutical development
2. TR business that supports research and development using our proprietary nasal drug delivery technology, and discovers promising seeds and groundbreaking technologies from domestic and international universities and research institutions
3. Medipolis business that leverages Kagoshima's natural capital for environmentally conscious projects (social benefit creation business)

The general flow (process) of pharmaceutical development is as follows.

Our company is Japan's first CRO. We provide seamless services from non-clinical to clinical stages and operate globally. For more details, Our Business Please see.

TR (Translational Research) means "bridging research" from basic research to clinical practice. AtSNBL , we are developing businesses that discover promising seeds and groundbreaking new technologies born from basic research at universities and bio-ventures in Japan and overseas, increase added value, and lead to commercialization. In addition, we are developing new drugs by applying our proprietary technology for administering nasal formulations. For details Here Please see.

SNBL was founded in 1957 in Kagoshima, Japan. We developed our business as the first CRO in Japan, listed on the Tokyo Stock Exchange in 2004, and have been listed on the Prime Market of the Tokyo Stock Exchange since 2022. The entire Group has about 3,000 employees, including affiliated companies.

For the fiscal year ending March 2024, on a consolidated basis, we recorded sales of 26.45 billion yen, operating profit of 3.47 billion yen, ordinary profit of 6.39 billion yen, and net profit attributable to the parent company's shareholders of 3.97 billion yen. The core CRO business continued to drive growth, and sales reached a record high for the second consecutive period. Operating profit, which had been setting record highs for four consecutive periods, decreased by 1.08 billion yen (20.6%) to 4.16 billion yen compared to the previous year. The main reason for this was the recording of 1.34 billion yen in expenses for half a year from the acquisition of Satsuma Corporation last June. The increase in costs due to strategically large upfront investments was also a factor in the profit decline. The dividend is maintained at a record high of 50 yen per share.

At SNBL , half of our employees are women, and there are people of various nationalities working there, as well as from outside Kagoshima Prefecture. Not only in the sciences, but also in a wide range of fields, including the humanities, many specialists support the development of the business. For details Here Please see.

In addition to Kagoshima, Wakayama, Tokyo, Osaka, and Nagano, we have bases in countries such as the United States, Cambodia, and Laos. We receive work requests from overseas clients and are thriving as a global company. For more details, Here Please see.

We are actively pursuing new initiatives to become a company where everyone can work happily and enjoyably. We believe that 'human resources' are the most important strategic core for building competitive advantage and differentiating from other companies, and we consider 'developing people' as the foundation of our management. For more details Here Please see.

The popular white tiger at Hirakawa Zoo in Kagoshima City was actually donated by SNBL . As the official top partner of Kagoshima United FC, a local soccer club that plays in the J3 league, we also contribute to regional revitalization and international friendship through soccer. Medipolis International Proton Therapy Center was established by our company and we support its operation. Over 6,500 cancer patients have already been treated there, contributing to improving their quality of life. We support the operation of the international school Veritas Gakuen, and support multicultural education for children (ages 0-6). Overseas, we have opened a free school in Cambodia, where about 200 children are studying. We built a yogurt and cheese factory in the Kingdom of Bhutan to improve infant mortality rates. For more information, Here Please see.